Seres Therapeutics Inc. (MCRB)
NASDAQ: MCRB
· Real-Time Price · USD
19.36
0.56 (2.98%)
At close: Sep 05, 2025, 3:59 PM
19.32
-0.23%
After-hours: Sep 05, 2025, 05:40 PM EDT
Seres Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
|---|---|---|---|---|
| License And Service Revenue | 5.28M | 13.96M | 8.68M | 4.27M |
| License And Service Revenue Growth | -62.19% | +60.78% | +103.32% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 10.25M | 11.89M | 12.46M | 12.71M | 11.64M | 13.91M | 3.48M | 19.43M | 28.05M | 22.47M | 22.4M | 18.38M | 20.34M | 18.57M | 20.51M | 19.56M | 17.45M | 11.74M | 10.6M | 7.55M | 6.49M | 6.14M | 5.78M | 5.9M | 5.57M | 7.5M | 7.53M | 7.59M | 8.7M | 8.78M | 8.79M | 8.12M | 8.37M | 8.76M | 8.45M | 7.97M | 8.97M | 7.21M | 5.89M | 4.71M | 3.56M | 2.61M |
| Selling, General, and Administrative Revenue Growth | -13.75% | -4.61% | -1.95% | +9.15% | -16.27% | +299.86% | -82.10% | -30.73% | +24.84% | +0.29% | +21.87% | -9.59% | +9.50% | -9.44% | +4.82% | +12.10% | +48.63% | +10.82% | +40.31% | +16.33% | +5.75% | +6.16% | -1.95% | +5.79% | -25.63% | -0.50% | -0.76% | -12.70% | -0.93% | -0.14% | +8.25% | -3.00% | -4.47% | +3.66% | +6.10% | -11.18% | +24.41% | +22.45% | +24.98% | +32.48% | +36.45% | n/a |
| Research and Development Revenue | 12.94M | 11.82M | 12.84M | 16.46M | 15.81M | 21.7M | 23.04M | 25.15M | 46.79M | 43.97M | 46.22M | 43.12M | 43.94M | 39.65M | 36.75M | 39.88M | 35.95M | 29.3M | 24.87M | 23.86M | 20.1M | 21.74M | 21.03M | 18.32M | 17.91M | 22.89M | 24.77M | 23.68M | 24.05M | 23.46M | 24.04M | 22.21M | 23.06M | 20.14M | 20.26M | 24.14M | 22.17M | 15.42M | 13.9M | 9.85M | 8.78M | 5.56M |
| Research and Development Revenue Growth | +9.46% | -7.94% | -21.99% | +4.14% | -27.17% | -5.82% | -8.39% | -46.24% | +6.42% | -4.87% | +7.20% | -1.86% | +10.81% | +7.88% | -7.85% | +10.93% | +22.70% | +17.84% | +4.22% | +18.72% | -7.56% | +3.38% | +14.82% | +2.30% | -21.77% | -7.59% | +4.61% | -1.57% | +2.53% | -2.42% | +8.25% | -3.69% | +14.48% | -0.56% | -16.10% | +8.88% | +43.84% | +10.91% | +41.12% | +12.14% | +57.96% | n/a |